AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02951624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonger
Description: longer breaks of physical activity
Study NCT02951624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermediate
Description: Intermediate breaks of physical activity
Study NCT01858207 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Arterial Chemoembolization
Description: traditional TACE, conventional TACE
Study NCT01858207 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: simultaneous multiple electrodes and switching RF controller
Study NCT01858207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
Study NCT03643302 — intervention group
Intervention type: DEVICE
Intervention: Version BF-1T26 electronic bronchoscope
Description: Interventions involving the therapy of airway clearance and bronchoalveolar lavage by Version BF-1T26 electronic bronchoscope
Study NCT02732288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.
Study NCT02497508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Study NCT02273362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO
Study NCT02273362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT02273362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02273362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00805129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus (RAD001) is a novel oral derivative of rapamycin. Everolimus will be administered orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take Everolimus in the morning, at the same time each day. Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free meal.
Study NCT01829698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tauroursodeoxycholic
Description: Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
Study NCT01829698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ursodeoxycholic acid
Description: ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
Study NCT02601222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Runzao zhiyang capsule
Description: Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
Study NCT02601222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Runzaozhiyang capsule agent simulation
Description: Runzaozhiyang capsule agent simulation：4 pills each time, 3 times a day, oral， Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
Study NCT02601222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea cream
Description: Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
Study NCT02601222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Urea cream
Description: Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
Study NCT01938846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 860585
Description: BI 860585 multiple dose escalation, once daily
Study NCT01938846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: exemestane once daily
Study NCT01938846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel once weekly
Study NCT02775097 — intervention group
Intervention type: DEVICE
Intervention: OCT
Description: OCT for all Arms
Study NCT00696735 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: injection cyclophosphamide doxorubicin (25 mg/m2), and teniposide (60 mg/m2)(600 mg/m2)on day 1 and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
Study NCT00696735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high dose therapy and autologous stem cell transplantation
Description: VCAP regimen 3 cycles , less than PR: 2-3 DHAP, stem cell collection, in vitro purging autologous stem cell transplantation with TBI and cyclophosphamide
Study NCT01007370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Tracheal intubation through a supraglottic airway device(LMA-Fastrach).
Study NCT01007370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Tracheal intubation through a supraglottic airway device(I-gel).
Study NCT04258124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control motor intervention
Description: The intervention through motor control will consist in the application of the protocol described by Hidalgo-Peréz et al. The objective of the application of the technique is to produce an increase in the strength of the deep cervical musculature. The exercises will be performed with the subject in different positions: supine, quadrupedic and standing position. The physiotherapist will be placed in standing position in front of the subject. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.
Study NCT01634503 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GX-188E administered by electroporation
Description: Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
Study NCT04551664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical management
Description: All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
Study NCT04551664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best medical management
Description: All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
Study NCT04551664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Description: In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy (recommended with Solitaire、EMBOTRAP、Trevo or Reco revascularization device) or aspiration thrombectomy (recommended with Penumbra) will be recommended as the primary treatment.
Study NCT03651817 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: Patients will be ventilated with anesthesia machine according to the group they belong to
Study NCT01833585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cell
Description: Peripheral blood mononuclear cell solution 59 cc will be injected to the gastrocnemius muscle of ischemic limb of patients with critical limb ischemia
Study NCT02810275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Folinic acid 5 mg, taking in the morning, daily, during four weeks
Study NCT02810275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule received 1 tablet, taking in the morning, during four weeks
Study NCT01655095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: PEG 2L at 1800hrs the night before the test and 2L at 0500hrs the morning of the test.
Study NCT01655095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 2mg will be administered at 0800hrs on the day of the test, at the same time the colon capsule is administered. Two hours later the position of the colon capsule will be assess with a Realtime Viewer. If the capsule has not reached the cecum a second dose of Prucalopride 2mg will be administered at that time.
Study NCT01655095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picosalax
Description: One sachet at 1800hrs the night before the test One sachet at 0500hrs the day of the test
Study NCT01655095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Description: Bisacodyl 10mg in the evening three nights before the procedure and 10mg again two nights before the procedure.
Study NCT01655095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon capsule
Description: The colon capsule will be ingested at 0800hrs the day of the test. Seven hours will be allowed for the capsule to clear the bowel. The images will be reviewed by two endoscopists with experience reading video capsule endoscopy.
Study NCT01655095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: At 1500hrs on the day of the test all individuals will return to the endoscopy unit for a colonoscopy.
Study NCT03097432 — intervention group
Intervention type: DRUG
Intervention: ORALVAC COMPACT BÄUME
Study NCT01345812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HP-HMG
Description: 100 - 300 IU for stimulation of women in ART treatment
Study NCT01345812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: 100 -300 IU for stimulation of women in ART treatment
Study NCT01388153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay ODT, BAYG5421)
Description: Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water
Study NCT01388153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay ODT, BAYG5421)
Description: Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water
Study NCT01388153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose (Glucobay, BAYG5421)
Description: Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
Study NCT04988334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait Control
Description: usual activities
Study NCT04988334 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wait Control
Description: usual activities
Study NCT04118647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wu-Chu-Yu tang
Description: Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.
Study NCT03969615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SuperNO2VA nasal positive airway pressure devic
Description: SuperNO2VA nasal positive airway pressure device utilizes supplemental oxygen and an adjustable pressure limiting valve to maintain upper airway latency
Study NCT03969615 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental oxygen
Description: 5lpm of supplemental oxygen
Study NCT03876483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual peer support group
Description: Intervention package will consist of a WhatsApp group setup and organized by the study. Participants will be divided into 1-3 WhatsApp groups, each with 10-55 youth. Each group will be facilitated by a study staff member trained as a counselor. The facilitator will send weekly messages to the group. Messages from the facilitator will not contain overtly HIV-related language. These messages are intended to spark unstructured discussion among study participants, or with the facilitator, at any time through the WhatsApp group or individually. Subsequent messages from the study will answer participant questions or correct misinformation. Standard operating procedures (SOPs) will be developed for standardizing responses to the questions received so that study staff follow national guidelines and local practice standards to respond.
Study NCT01070433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEBO Wound Ointment (MEBO)
Description: Topical application twice a day
Study NCT01070433 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Topical application twice a day
Study NCT00674206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m\^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
Study NCT00674206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 100mg/m\^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
Study NCT02010112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Test Collection bags
Description: Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
Study NCT03562858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate dentin sealing protocol
Description: Sealing of the dentin before impression taking directly after cavity preparation to prevent postoperative hypersensitivity during provisionalization and after cementation
Study NCT03562858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed dentin sealing protocol
Description: Sealing the dentin just prior to cementation
Study NCT03285945 — intervention group
Intervention type: DRUG
Intervention: PET3
Description: Prednisolone 60 mg daily for 3 days
Study NCT03285945 — intervention group
Intervention type: DRUG
Intervention: PET10
Description: Prednisolone 60 mg daily for 10 days
Study NCT04298580 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVB block
Description: PVB block before surgery versus after surgery
Study NCT03560869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal hydration
Description: see description in 'arms'
Study NCT03560869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: see description in 'arms'
Study NCT04350645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: 1g slow bolus of tranexamic acid over 2 minutes
Study NCT04350645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: 10mls normal saline 0.9% over 2 minutes
Study NCT01137097 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral sentinel lymph node biopsy
Description: Sentinel lymph node biopsy with radioisotope. Isotope injection and lymphoscintigraphy preoperatively
Study NCT03921476 — intervention group
Intervention type: OTHER
Intervention: Online survey
Description: Online survey completion through Northwestern's REDCap
Study NCT02870556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cervical epidural analgesia
Study NCT02870556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cervical epidural analgesia
Study NCT00834847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin
Description: 40 mg tablet
Study NCT00834847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravachol®
Description: 40 mg Tablet
Study NCT01857180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curriculum
Study NCT01419535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 50mg tablet by mouth every six hours for nine days.
Study NCT01419535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.
Study NCT04655326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flore
Description: personalized blend of GRAS approved probiotic strains, prebiotics, and botanicals
Study NCT00478712 — intervention group
Intervention type: OTHER
Intervention: Identification of genetic causes of Hirschsprung Disease
Description: Blood, saliva, or DNA samples are requested from all study participants. The blood or saliva samples are used to isolate DNA in all participants. Blood samples are also used to establish cell lines in some participants.
Study NCT03767426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Description: Subjects are sleep deprived for an entire night
Study NCT03767426 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Deprivation
Description: Subjects are sleep deprived for an entire night
Study NCT03767426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daytime nap
Description: After a night of sleep deprivation, participants will be given a 2 hour nap opportunity
Study NCT00810498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trilogy
Description: Exposure for one hour on the Trilogy ventilator
Study NCT00810498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Exposure to participants current ventilator
Study NCT03478085 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen guided exercise therapy
Description: Subjects exercise to a certain intensity based on 15% muscle oxygen desaturation.
Study NCT03478085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen guided exercise therapy
Description: Subjects exercise to a certain intensity based on 15% muscle oxygen desaturation.
Study NCT03478085 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen guided exercise therapy
Description: Subjects exercise to a certain intensity based on 15% muscle oxygen desaturation.
Study NCT02099253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 01
Description: Initial doses was 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
Study NCT02099253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 02
Description: Initial doses was 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
Study NCT01962948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT01962948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganetespib
Description: Given IV
Study NCT01962948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02422004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Range of motion
Description: 25 range of motion exercises of the ankle, 5 times per day.
Study NCT02422004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Range of motion
Description: 25 range of motion exercises of the ankle, 5 times per day.
Study NCT02422004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed weight-bearing
Description: No weight-bearing during the first six weeks, and partial weight-bearing during the two following weeks
Study NCT04227405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connection to community services through case management
Description: Case managers met with couple and conduct a needs assessment for the couple and their family. Then they developed an Individual and Couple Development Plan to take care of those needs, usually by accessing community services. Case managers met every 5 weeks with the couple to check on progress toward meeting the goals of the plan and assess for the present of any new needs.